1832 Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-440,145	Closed	-$175M	–	653
2025 Q4	$175M	Sell	440,145 -19,200	-4%	-$8.5M	0.13%	108
2025 Q3	$209M	Buy	459,345 +236,000	+106%	+$96.1M	0.17%	73
2025 Q2	$72.8M	Buy	223,345 +79,300	+55%	+$21.9M	0.06%	162
2025 Q1	$38.9M	Buy	+144,045	New	+$37M	0.04%	221
2024 Q3	–	Sell	-545	Closed	-$132K	–	680
2024 Q2	$132K	Hold	545	–	–	﹤0.01%	658
2024 Q1	$81.5K	Hold	545	–	–	﹤0.01%	676
2023 Q4	$104K	Hold	545	–	–	﹤0.01%	655
2023 Q3	$96.5K	Hold	545	–	–	﹤0.01%	668
2023 Q2	$104K	Sell	545 -22,200	-98%	-$4.4M	﹤0.01%	670
2023 Q1	$4.56M	Sell	22,745 -368,600	-94%	-$77.5M	0.01%	415
2022 Q4	$93M	Buy	391,345 +4,200	+1%	+$896K	0.15%	120
2022 Q3	$77.5M	Buy	387,145 +386,600	+70,936%	+$73.7M	0.14%	137
2022 Q2	$79K	Hold	545	–	–	﹤0.01%	724
2022 Q1	$88K	Buy	+545	New	+$83K	﹤0.01%	757
2020 Q2	–	Sell	-20,900	Closed	-$2.29M	–	645
2020 Q1	$2.29M	Buy	+20,900	New	+$2.41M	0.01%	388